Unlike MTLn3 tumors in the rat immunocompetent model, human JIMT-1 breast cancer cells are resistant to Fab-mediated effects of Trastuzumab [8, 9] and of our human IgE 26. This evidence concerns the gene IGHE and breast carcinoma.